A Study of KRN23 in Adult and Pediatric Patients With X-linked Hypophosphatemic Rickets/Osteomalacia

XLH Clinical Trial

Official title:

A Phase 3 Long-term Extension Study of KRN23 in Patients With X-linked Hypophosphatemic Rickets/Osteomalacia and a Post-marketing Study of KRN23 Switched From the Phase 3 Long-term Extension Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04308096
• Other study ID #: KRN23-004
• Status: Completed
• Phase: Phase 3
• Start date: January 9, 2018
• Est. completion date: December 4, 2020

Study information

• Verified date: September 2022
• Source: Kyowa Kirin Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Before switching to the post-marketing study: Assess the efficacy and safety of KRN23 administered subcutaneously once every 4 or 2 weeks in adult or children with XLH After switching to the post-marketing study: To evaluate the safety and efficacy of KRN23, which was switched from the investigational product to the post-marketing investigational product, at the approved dose and dosing regimen in subjects who continued treatment

Recruitment information / eligibility

• Status: Completed
• Enrollment: 27
• Est. completion date: December 4, 2020
• Est. primary completion date: December 4, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

1. Personally submitted voluntary written informed consent to participate in the study; For pediatric patients, personally submitted voluntary written informed consent by a legally authorized representative. If appropriate, written or verbal assent to participate in the study should be obtained from patients.

2. Patients meeting any of the followings;

1. For adult XLH patients, completion the final observation at Week 96 in UX023-CL303 or UX023-CL304

2. For pediatric patients, completion the final observation at Week 64 in UX023-CL301

3. For female patients; women of childbearing potential (except for females who have not reached menarche, permanently sterilized, postmenopausal [12 months with no menses without an alternative medical cause] or anatomically not of childbearing potential) with negative pregnancy test at pre-treatment assessment of Week 0

4. For female patient with childbearing potential, or male patients with reproductive capacity; willingness to use acceptable methods of contraception while participating in the study

5. Willingness and ability to cooperatively complete all study procedures, adhere to the visit schedule and follow the investigator's instructions, as considered by investigator or subinvestigator

Exclusion Criteria:

1. Use of oral phosphate for treating XLH, pharmacologic vitamin D metabolites or analogs, aluminum hydroxide antacids, systemic corticosteroids, acetazolamide, and thiazides within 7 days prior to scheduled initial administration of investigational drug

2. Planned or recommended orthopedic surgery (implantation or removal), including staples, 8 plates or osteotomy, during the study period

3. Blood or blood product transfusion within 60 days prior to scheduled initial administration of investigational drug

4. Use of growth hormone therapy within 12 months prior to scheduled initial administration of investigational drug

5. Use of medication to suppress the secretion of parathyroid hormone (e.g., cinacalcet) within 60 days prior to scheduled initial administration of investigational drug

6. Use of any investigational product (except for investigational product of the preceding study) or investigational medical device within 4 months prior to scheduled initial administration of investigational drug, or requirement for any investigational agent prior to completion of all scheduled study assessments

7. Use of a therapeutic monoclonal antibody other than KRN23 within 90 days prior to scheduled initial administration of investigational drug

8. History of being positive for HIV antibody, HBs antigen and/or HCV antibody

9. Anyone otherwise considered unsuitable for the study by the investigator or subinvestigator At the time of switching to the post-marketing clinical study: Subjects eligible for enrollment in the post-marketing clinical study must have met both of

the following criteria:

1. Personally submitted voluntary written informed consent to participate in the postmarketing clinical study. For pediatric patients, personally submitted voluntary written informed consent by a legally authorized representative. If appropriate, written or verbal assent to participate in the post-marketing clinical study was to be obtained from subjects.

2. Switching to the post-marketing clinical study was necessary and appropriate for the subject from the viewpoint of efficacy and safety, as judged by the investigator or subinvestigator

Related Conditions & MeSH terms

• Familial Hypophosphatemic Rickets
• Osteomalacia
• Rickets
• XLH

Intervention

Drug:
• KRN23
The starting dose of KRN23 will be the dose used for the last administration in the preceding studies. The dose may be modified subsequently in accordance with the criteria for dose and dose adjustment.

Locations

Country	Name	City	State
Japan	The University of Tokyo Hospital	Bunkyo-Ku	Tokyo
Japan	Toranomon Hospital	Minato-Ku	Tokyo
Japan	Okayama Saiseikai General Hospital	Okayama
Japan	Japan Community Health Care Organization Osaka Hospital	Osaka
Japan	Osaka City University Hospital	Osaka
Japan	Hokkaido University Hospital	Sapporo	Hokkaido
Japan	National University Corporation Osaka University	Suita	Osaka
Japan	Kanagawa Prefectural Hospital Organization Kanagawa Children's Medical Center	Yokohama	Kanagawa
Korea, Republic of	Asan Medical Center	Seoul	Korea
Korea, Republic of	Seoul National University hospital	Seoul	Korea

Sponsors (1)

Lead Sponsor	Collaborator
Kyowa Kirin Co., Ltd.

Countries where clinical trial is conducted

Japan,  Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Pharmacokinetics (Serum KRN23 concentration)		up to week 140
Other	Immunogenicity (Anti-KRN23 Antibody)		up to week 140
Primary	Number of subjects for each adverse events		up to week 140
Primary	Effect to Body temperature		up to week 140
Primary	Effect to Pulse rate		up to week 140
Primary	Effect to Respiratory rate		up to week 140
Primary	Effect to Systolic blood pressure in sitting position		up to week 140
Primary	Effect to Diastolic blood pressure in sitting position		up to week 140
Primary	Effect to 12-lead electrocardiogram (ECG)	The presence of abnormality in the electrocardiogram	up to week 140
Primary	Effect to renal ultrasound	The evaluation to nephrocalcinosis in five grades by renal ultrasound	up to week 140
Primary	Effect to Echocardiogram	The presence of ectopic calcification in the heart by Echocardiogram	up to week 140
Secondary	Concentration of serum phosphorus		up to week 140
Secondary	Concentration of serum 1,25(OH)2D		up to week 140
Secondary	Concentration of urinary phosphorus		up to week 140
Secondary	Concentration of tubular resorption of phosphorus(TRP)		up to week 140
Secondary	Concentration of maximum tubular reabsorption of phosphate/glomerular filtration rate (TmP/GFR)		up to week 140
Secondary	concentration of Carboxy terminal cross-linked telopeptide of type 1 collagen (CTx) (Adult patients with XLH)		up to week 140
Secondary	concentration of Procollagen type 1 N-propeptide (P1NP) (Adult patients with XLH)		up to week 140
Secondary	concentration of Bone-specific alkaline phosphatase (BALP)(Adult patients with XLH)		up to week 140
Secondary	Concentration of serum alkaline phosphatase (ALP) (Pediatric patients with XLH)		up to week 140
Secondary	Motor functions (6 minutes walk test (6MWT))		up to week 140
Secondary	Radiographic findings of fracture and enthesopathy (Adult patients with XLH)	The presence of radiographic fracture and enthesopathy assessed by X-ray (Adult patients with XLH)	up to week 140
Secondary	Rickets Severity Score (RSS) (Pediatric patients with XLH)		up to week 140
Secondary	Radiographic Global Impression of Change (RGI-C)(Pediatric patients with XLH)		up to week 140
Secondary	Z score of height (LMS method) (Pediatric patients with XLH)		up to week 140